Eirion Therapeutics Announces Strategic Agreement
Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer.
Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer.
HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials.
HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools